Back to search results

Empagliflozin for Peritoneal and Kidney Function in End Stage Renal Disease

This study is looking at how a medication called empagliflozin (25 mg or 10 mg) affects people with End Stage Renal Disease (ESRD) who are on peritoneal dialysis (PD). The main goal is to see if empagliflozin can reduce how much sugar (glucose) is absorbed in your belly (peritoneum). You might be able to join if you are over 18, have been on PD for more than 3 months, and have a working PD catheter. People with certain types of diabetes or frequent low blood sugar are not able to join. This study is currently unclear about its recruitment status and plans to enroll about 30 participants.

Study design
This is a randomized, placebo-controlled study with an initial crossover phase, followed by an open-label extension. About 30 participants will be involved.
What's involved
You will have three main study visits and up to four safety visits over nine weeks. You will take empagliflozin or a placebo, and undergo a PET test at each visit.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, glucose absorption, is measured from Day 0 to Day 63.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05671991

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Active, Not Recruiting
PHASE4Ages 18+Interventional
Yale University
~22 participants
Updated 2026-09-14 on ClinicalTrials.gov
What's tested:Empagliflozin 25 mg vs PlaceboEmpagliflozin 10 MG

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Glucose absorption with empagliflozin vs. placebo
Measured over Day 0 to Day 63

Conditions

End Stage Renal Disease on Dialysis

Explore related trials

Chronic Kidney Disease, Stage 5Peritoneal Dialysis

NCT05671991

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Yale University

    New Haven, Connecticutno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jeffrey Testani, MD · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Glucose absorption with empagliflozin vs. placeboDay 0 to Day 63

    Total glucose absorption in grams with empagliflozin vs. placebo